Are fusion inhibitors active against all HIV variants?

AIDS Res Hum Retroviruses. 2004 Mar;20(3):347-8. doi: 10.1089/088922204322996590.

Abstract

Genetic sequence alignment of the transmembrane region from HIV-1 group O and HIV-2 isolates was performed to examine their potential susceptibility to fusion inhibitors enfuvirtide (T-20) and T-1249. A high genetic diversity within the HRI and HR2 domains was found, which should compromise any antiviral effect of T-20 on HIV-2 and HIV-1 group O viruses. However, conserved sequences in the gp41 regions from HIV-1 group O involved in T-1249 susceptibility might result in a much broader antiviral effect of T-1249 on HIV-1 variants. In contrast, genetic diversity in those regions make unlikely any activity of these compounds on HIV-2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Drug Resistance, Viral
  • Enfuvirtide
  • Genetic Variation*
  • HIV Envelope Protein gp41 / chemistry*
  • HIV Envelope Protein gp41 / genetics
  • HIV Envelope Protein gp41 / pharmacology
  • HIV Fusion Inhibitors / pharmacology*
  • HIV-1 / classification
  • HIV-1 / drug effects*
  • HIV-1 / genetics
  • HIV-2 / classification
  • HIV-2 / drug effects*
  • HIV-2 / genetics
  • Humans
  • Peptide Fragments / pharmacology
  • Sequence Alignment

Substances

  • HIV Envelope Protein gp41
  • HIV Fusion Inhibitors
  • Peptide Fragments
  • peptide T1249
  • Enfuvirtide